NCT07226986 2026-02-17
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT05682443 2025-12-02
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06574880 2025-11-24
STARLiT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06785636 2025-11-14
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
NCT05113537 2025-09-18
UPLIFT
University of California, San Francisco
Phase 1/2 Recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT05340374 2025-04-06
LuCAB
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT04430192 2024-11-08
LuTectomy
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT03545165 2021-08-24
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT03828838 2019-11-14
Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer
Radboud University Medical Center
Phase 1/2 Completed